title: Association between the FCGR3A V158F polymorphism and the clinical response to infliximab in rheumatoid arthritis and spondyloarthritis patients.
authors.forename: M J
authors.initials: MJ
authors.lastname: Morales-Lara
authors.forename: P
authors.initials: P
authors.lastname: Conesa-Zamora
authors.forename: M S
authors.initials: MS
authors.lastname: García-Simón
authors.forename: F
authors.initials: F
authors.lastname: Pedrero
authors.forename: V
authors.initials: V
authors.lastname: Santaclara
authors.forename: M
authors.initials: M
authors.lastname: Perez-Guillermo
authors.forename: E
authors.initials: E
authors.lastname: Soriano-Navarro
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D018501:Antirheumatic Agents / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy* / Q000235:genetics; D056726:Genetic Association Studies; D006801:Humans; D000069285:Infliximab; D020641:Polymorphism, Single Nucleotide; D017452:Receptors, IgG / Q000235:genetics*; D012720:Severity of Illness Index; D013167:Spondylitis, Ankylosing / Q000188:drug therapy* / Q000235:genetics
chemical_list: D000911:Antibodies, Monoclonal; D018501:Antirheumatic Agents; C496124:FCGR3A protein, human; D017452:Receptors, IgG; D000069285:Infliximab